134168-97-1

Usage

Uses

Used in Pharmaceutical Industry:
3-Fluoro-5-bromoaniline is used as an intermediate chemical for the synthesis of various pharmaceuticals. Its unique structure allows it to be a key component in the development of new drugs, contributing to the advancement of medicine.
Used in Dye Industry:
3-Fluoro-5-bromoaniline is used as a chemical intermediate in the production of dyes. Its properties enable it to be incorporated into the manufacturing process of a wide range of dyes, enhancing the color spectrum and quality of the final products.
Used in Chemical Research:
3-Fluoro-5-bromoaniline is used as a research compound in the field of organic chemistry. Its distinct structure makes it an interesting subject for studying chemical reactions and exploring new synthetic pathways, furthering the understanding of chemical processes and potential applications.

Upstream product

• 7087-65-2 1-bromo-3-fluoro-5-nitrobenzene 
• 807620-95-7 N-(3-bromo-5-fluorophenyl)acetamide 
• 364-78-3 2-nitro-4-fluoroaniline 
• 7439-89-6 iron 
• 10472-88-5 4-fluoro-2-bromo-6-nitroaniline 
• 1435-51-4 1,3-dibromo-5-fluorobenzene 

Downstream Products

• 210992-28-2 3-amino-5-fluoro-benzonitrile 
• 1026951-54-1 3-[4-(3-bromo-5-fluoro-phenyl)-piperazin-1-yl]-1-(5-methyl-1-pyrimidin-2-yl-1H-pyrazol-4-yl)-propan-1-one 
• 134168-96-0 N-(3-bromo-5-fluorophenyl)-N'-t-pentylthiourea 
• 181633-36-3 3-fluoro-5-(3'-pyridyl)phenylamine 
• 181629-93-6 SB 228357 
• 710348-96-2 N-(3-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanesulfonamide 

Relevant academic research and scientific papers

NOVEL COMPOUND FOR ORGANIC ELECTROLUMINESCENT DEVICE AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING THE SAME

Provided are a compound for an organic light emitting device and an organic light emitting device comprising the same. To this end, it is possible to provide a compound for an organic light emitting device which can be used as a host, a hole-transport material, or an electron-transport material capable of enhancing light-emitting efficiency of phosphorescent light-emitting materials by having outstanding electrical stability, an electron and hole transportability, and a high level of triplet state energy, and the organic light emitting device.

COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS

The present invention relates to compounds that demonstrate antibacterial activity, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans. In particular this invention relates to compounds useful for the treatment of bacterial infections in warm-blooded animals such as humans, more particularly to the use of these compounds in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans.

3-[Substituted]-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitriles: Identification of highly potent and selective metabotropic glutamate subtype 5 receptor antagonists

Structure-activity relationship studies on the phenyl ring of 3-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitrile 2 led to the discovery that small, non-hydrogen bond donor substituents at the 3-position led to a substantial increase in in vitro potency. In particular, 3-fluoro-5-(5-pyridin- 2-yl-2H-tetrazol-2-yl)benzonitrile (7) is a highly potent and selective mGlu5 receptor antagonist with good rat pharmacokinetics, brain penetration, and in vivo receptor occupancy.

3-[3-Fluoro-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)phenyl]-4-methylpyridine: A highly potent and orally bioavailable metabotropic glutamate subtype 5 (mGlu5) receptor antagonist

Structure-activity relationship studies performed around 3-fluoro-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitrile for the purposes of developing novel mGlu5 receptor antagonists are described. Synthesis of a series of four-ring tetrazoles led to the discovery of 3-[3-fluoro-5-(5-pyridin-2-yl- 2H-tetrazol-2-yl)phenyl]-4-methylpyridine (26), a highly potent, brain penetrant, tetrazole-based mGlu5 receptor antagonist. Structure-activity relationship studies performed around 3-fluoro-5-(5-pyridin-2-yl-2H-tetrazol-2- yl)benzonitrile for the purpose of developing novel mGlu5 receptor antagonists are described. Synthesis of a series of four-ring tetrazoles led to the discovery of 3-[3-fluoro-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)phenyl]-4- methylpyridine, a highly potent, brain penetrant, azole-based mGlu5 receptor antagonist.

Biologically selective potassium channel openers having 1,1- diethylpropyl group

To find out selective potassium channel openers (PCOs), we synthesized several 3,5-disubstituted phenylcyanoguanidine derivatives and investigated their structure-activity relationships (SAR). As a result, we discovered selective PCOs having 1,1-diethylpropyl group toward antihypertensive activity.

NMDA antagonists

The present invention is directed to a new class of 4-sulfanimide-quinoline derivatives and to their use as NMDA antagonists.

Novel cyanoguanidine derivatives

Compounds of the formula: STR1 wherein R1 and R2 are independently fluorine, chlorine or bromine atom, and R3 is a C4 -C7 alkyl having at least a branch at the C1 position, exhibit K+ channel opening activity and are useful as hypotensive agents and coronary vasodilators.